Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital |
---|---|
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00165503 |
The purposes of this study are: to determine the feasibility of administering adjuvant cisplatin plus ALIMTA to patients who undergo surgery with heated cisplatin during surgery; to determine the effects (good and bad) of this combined modality approach in patients with mesothelioma; to evaluate cisplatin effects by determining where it goes and how it is excreted in the body from the collection of tissues and cisplatin samples; to collect and analyze discarded samples of mesothelioma tumor during surgery to help determine the genetic make-up of the disease.
Condition | Intervention | Phase |
---|---|---|
Pleural Mesothelioma Malignant Pleural Mesothelioma |
Drug: Cisplatin Drug: Sodium Thiosulfate Drug: ALIMTA |
Phase II |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin |
Estimated Enrollment: | 55 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: David J. Sugarbaker, MD | 617-732-5004 |
United States, Massachusetts | |
Brigham and Women's Hospital | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Principal Investigator: David J. Sugarbaker, MD | |
Dana-Farber Cancer Institute | Active, not recruiting |
Boston, Massachusetts, United States, 02115 |
Principal Investigator: | David J. Sugarbaker, MD | Brigham and Women's Hospital |
Responsible Party: | Brigham and Women's Hospital ( David Sugarbaker, MD ) |
Study ID Numbers: | 04-063 |
Study First Received: | September 12, 2005 |
Last Updated: | January 30, 2009 |
ClinicalTrials.gov Identifier: | NCT00165503 History of Changes |
Health Authority: | United States: Institutional Review Board |
pleurectomy decortication cisplatin ALIMTA |
Antimetabolites Anti-Infective Agents Antioxidants Sodium thiosulfate Adjuvants, Immunologic Folate Folinic Acid Folic Acid Antagonists Vitamin B9 Folic Acid |
Pemetrexed Anti-Bacterial Agents Cisplatin Radiation-Sensitizing Agents Mesothelioma Antitubercular Agents Chelating Agents Adenoma Neoplasms, Glandular and Epithelial |
Antimetabolites Anti-Infective Agents Antioxidants Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Neoplasms, Mesothelial Physiological Effects of Drugs Anti-Bacterial Agents Cisplatin Therapeutic Uses Antidotes Neoplasms by Histologic Type |
Sodium thiosulfate Enzyme Inhibitors Folic Acid Antagonists Protective Agents Pharmacologic Actions Pemetrexed Neoplasms Radiation-Sensitizing Agents Mesothelioma Antitubercular Agents Chelating Agents Adenoma Neoplasms, Glandular and Epithelial |